세계의 mRNA 플랫폼 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 적응증별, 유용성별, mRNA 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Usability, By mRNA Type, By End User, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,508,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,954,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,570,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 mRNA 플랫폼 시장은 2024년 73억 달러로 평가되었고, 2030년까지 연평균 성장률(CAGR) 3.56%로 성장할 것으로 예측됩니다.

mRNA(메신저 RNA) 플랫폼은 합성 RNA 분자를 통해 세포에 유전적 지시를 전달하여 특정 단백질 생산을 촉진하는 고급 생물공학 혁신 기술입니다. 특히 2023년 9월, BioNTech SE는 CEPI와 협력해 mRNA 기반 Mpox 백신 개발을 가속화하기로 합의했으며, 이는 플랫폼이 신종 감염병 위협 대비에 중요한 역할을 강조합니다. 합성 mRNA 서열은 체내 RNA의 자연적 역할을 모방해 면역 반응을 유도하거나 치료용 단백질 생산을 지원하도록 설계되었습니다. 이 기술들은 적응성, 개발 속도, 효과성 때문에 특히 공중 보건 위기 및 맞춤형 의료 응용 분야에서 점점 더 널리 채택되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	73억 달러
시장 규모(2030년)	89억 3,000만 달러
CAGR(2025-2030년)	3.56%
급성장 부문	자기 증폭형 mRNA
최대 시장	북미

시장 성장 촉진요인

기술 발전

주요 시장 과제

백신 접종 거부감과 허위 정보

주요 시장 동향

가상 평가판 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 적응증별(자가면역질환, 암, 감염증, 희귀 질환, 호흡기질환)
  • 유용성별(예방 백신, 치료제, 치료 백신)
  • mRNA 유형별(핵산 변형 mRNA, 자기 증폭형 mRNA, 비변형 mRNA)
  • 최종 사용자별(병원 및 진료소, 제약 회사, 연구기관)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 mRNA 플랫폼 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 mRNA 플랫폼 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Amgen Inc. AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• Baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F및E GmbH 및 Co KG

제17장 전략적 제안

제18장 기업 소개와 면책사항

HBR

영문 목차

영문목차

The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected to grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.30 Billion
Market Size 2030	USD 8.93 Billion
CAGR 2025-2030	3.56%
Fastest Growing Segment	Self-Amplifying mRNA
Largest Market	North America

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Market Players

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

• Autoimmune Diseases
• Cancer
  • Personalized Treatment
  • Single Cancer Focused
• Infectious Diseases
• Rare Diseases
• Respiratory Diseases

mRNA Platform Market, By Usability:

• Prophylactic Vaccines
• Therapeutic Drugs
• Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

• Nucleoside-Modified mRNA
• Self-Amplifying mRNA
• Unmodified mRNA

mRNA Platform Market, By End-User:

• Hospitals & Clinics
• Pharmaceutical Companies
• Research Organization

mRNA Platform Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
  • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
  • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
  • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Usability
  • 6.2.3. By mRNA Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China mRNA Platform Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Usability
      • 6.3.1.2.3. By mRNA Type
      • 6.3.1.2.4. By End User
  • 6.3.2. India mRNA Platform Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Usability
      • 6.3.2.2.3. By mRNA Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Australia mRNA Platform Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Usability
      • 6.3.3.2.3. By mRNA Type
      • 6.3.3.2.4. By End User
  • 6.3.4. Japan mRNA Platform Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Usability
      • 6.3.4.2.3. By mRNA Type
      • 6.3.4.2.4. By End User
  • 6.3.5. South Korea mRNA Platform Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Usability
      • 6.3.5.2.3. By mRNA Type
      • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Usability
  • 7.2.3. By mRNA Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France mRNA Platform Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Usability
      • 7.3.1.2.3. By mRNA Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany mRNA Platform Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Usability
      • 7.3.2.2.3. By mRNA Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Spain mRNA Platform Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Usability
      • 7.3.3.2.3. By mRNA Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy mRNA Platform Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Usability
      • 7.3.4.2.3. By mRNA Type
      • 7.3.4.2.4. By End User
  • 7.3.5. United Kingdom mRNA Platform Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Usability
      • 7.3.5.2.3. By mRNA Type
      • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Usability
  • 8.2.3. By mRNA Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States mRNA Platform Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Usability
      • 8.3.1.2.3. By mRNA Type
      • 8.3.1.2.4. By End User
  • 8.3.2. Mexico mRNA Platform Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Usability
      • 8.3.2.2.3. By mRNA Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Canada mRNA Platform Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Usability
      • 8.3.3.2.3. By mRNA Type
      • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Usability
  • 9.2.3. By mRNA Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil mRNA Platform Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Usability
      • 9.3.1.2.3. By mRNA Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina mRNA Platform Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Usability
      • 9.3.2.2.3. By mRNA Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia mRNA Platform Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Usability
      • 9.3.3.2.3. By mRNA Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Usability
  • 10.2.3. By mRNA Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa mRNA Platform Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Usability
      • 10.3.1.2.3. By mRNA Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Usability
      • 10.3.2.2.3. By mRNA Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE mRNA Platform Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Usability
      • 10.3.3.2.3. By mRNA Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amgen Inc. AstraZeneca PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Asuragen, Inc.
• 16.3. Catalent Pharma Solutions
• 16.4. Arcturus Therapeutics, Inc.
• 16.5. BioNTech AG
• 16.6. CRISPR Therapeutics Inc.
• 16.7. AKESOgen, Inc.
• 16.8. Baseclick GmbH
• 16.9. Accent Therapeutics Inc.
• 16.10.Accanis Biotech F&E GmbH & Co KG

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료